{
    "clinical_study": {
        "@rank": "50253", 
        "acronym": "PFN", 
        "arm_group": [
            {
                "arm_group_label": "Pediatric Invasive Candidiasis", 
                "description": "Pediatric patients (age > 120 days and < 18 years) with documented proven or probable invasive candidiasis"
            }, 
            {
                "arm_group_label": "Pediatric patients with other invasive fungal infections", 
                "description": "Patients with proven or probable invasive fungal infection that are not Candida, to be collected for general epidemiologic information"
            }
        ], 
        "brief_summary": {
            "textblock": "The overarching objective is to ultimately develop new evidence-based treatment guidelines\n      for invasive fungal infections in children.  To accomplish that, this protocol will focus on\n      two specific aims: 1) Compare the effectiveness of echinocandin versus amphotericin B or\n      triazole antifungal therapy for pediatric invasive candidiasis; 2) Characterize the\n      incidence of pediatric invasive candidiasis."
        }, 
        "brief_title": "International Pediatric Fungal Network", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Pediatric Invasive Candidiasis", 
        "condition_browse": {
            "mesh_term": [
                "Candidiasis", 
                "Candidiasis, Invasive"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a multicenter, national and international, prospective observational\n      comparative effectiveness study which also employs a case-control study design based on\n      prospectively identified cases and controls, as well as a general epidemiology database.\n\n      The primary aim of this study is to compare the effectiveness of echinocandin versus\n      amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis.  In order\n      to accomplish the first aim, this study will utilize a controlled comparative effectiveness\n      study design. The primary effectiveness endpoint for study aim 1 is the comparison of global\n      response at 14 days of antifungal therapy between antifungal therapeutic classes.  The\n      secondary effectiveness endpoints for study aim 1 are comparative effectiveness of the 1)\n      global response to antifungal therapy after 35 days and 2) all-cause mortality at 35 days.\n\n      The secondary aim is to characterize the frequency of pediatric candidiasis.  For this aim,\n      the investigators will use descriptive statistics to establish the frequency of hospital\n      admissions involving an invasive candidiasis per total hospital admissions and total\n      hospital days during the study period.  The endpoint for aim 2 is to describe the incidence\n      of pediatric candidiasis relative to all pediatric admissions."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males or females age > 120 days and <18 years\n\n          2. Incident case of invasive candidiasis\n\n          3. Parental/guardian permission (informed consent, if required) and if appropriate,\n             child assent (if required).\n\n        Exclusion Criteria:\n\n        1) Any history of prior Candida infection within the previous 35 days (These patients will\n        not be eligible for analysis in aim 1 but will be eligible for inclusion of aim 2)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "120 Days", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Pediatric patients with invasive candidiasis"
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01869829", 
            "org_study_id": "Pro00045657", 
            "secondary_id": "1R01AI103315-01A1"
        }, 
        "intervention": {
            "arm_group_label": [
                "Pediatric Invasive Candidiasis", 
                "Pediatric patients with other invasive fungal infections"
            ], 
            "description": "Observational study of primary antifungal therapy utilized and outcomes, including:\nfluconazole, voriconazole, amphotericin B, caspofungin, and micafungin\nAntifungal agents agreed upon (and dosing) at each site.\nAll agents are given as standard of care.", 
            "intervention_name": "Observational antifungal therapy", 
            "intervention_type": "Drug", 
            "other_name": [
                "fluconazole", 
                "voriconazole", 
                "amphotericin B", 
                "caspofungin", 
                "micafungin"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amphotericin B", 
                "Liposomal amphotericin B", 
                "Antifungal Agents", 
                "Clotrimazole", 
                "Miconazole", 
                "Fluconazole", 
                "Voriconazole", 
                "Caspofungin", 
                "Micafungin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Candida", 
            "Pediatric", 
            "Antifungal"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "link": {
            "description": "International Pediatric Fungal Network", 
            "url": "http://pfn.pediatrics.duke.edu"
        }, 
        "location": [
            {
                "contact": {
                    "email": "bill.steinbach@duke.edu", 
                    "last_name": "William J Steinbach, MD", 
                    "phone": "919-684-3734"
                }, 
                "contact_backup": {
                    "email": "ava.brozovich@duke.edu", 
                    "last_name": "Ava A Brozovich, MPH", 
                    "phone": "919-668-4847"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zaoutis@email.chop.edu", 
                    "last_name": "Theoklis E Zaoutis, MD", 
                    "phone": "267-426-5570"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Children's Hospital of Philadelphia"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "International Pediatric Fungal Network: Multi-Center Studies to Improve Diagnosis and Treatment of Pediatric Candidiasis", 
        "other_outcome": {
            "description": "The tertiary objective is to characterize the frequency of all invasive fungal infections in pediatric patients.  For the third aim, the investigators will use descriptive statistics to establish the frequency of hospital admissions involving an invasive fungal infection per total hospital admissions and total hospital days during the study period.  The endpoint for aim 3 is to describe the incidence of pediatric invasive fungal infections relative to all pediatric admissions.", 
            "measure": "Describe incidence of pediatric invasive fungal infections", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "overall_contact": {
            "email": "bill.steinbach@duke.edu", 
            "last_name": "William J Steinbach, MD", 
            "phone": "919-684-3734"
        }, 
        "overall_official": [
            {
                "affiliation": "Duke University", 
                "last_name": "William J Steinbach, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Children's Hospital of Philadelphia", 
                "last_name": "Theoklis E Zaoutis, MD MSCE", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary aim of this study is to compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis.  In order to accomplish the first aim, this study will utilize a controlled comparative effectiveness study design. The primary effectiveness endpoint for study aim 1 is the comparison of global response at 14 days of antifungal therapy between antifungal therapeutic classes.  The secondary effectiveness endpoints for study aim 1 are comparative effectiveness of the 1) global response to antifungal therapy after 30 days and 2) all-cause mortality at 30 days.", 
                "measure": "Global response to antifungal therapy at day 14", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "The primary aim of this study is to compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis. In order to accomplish the first aim, this study will utilize a controlled comparative effectiveness study design. The primary effectiveness endpoint for study aim 1 is the comparison of global response at 14 days of antifungal therapy between antifungal therapeutic classes. The secondary effectiveness endpoints for study aim 1 are comparative effectiveness of the 1) global response to antifungal therapy after 35 days and 2) all-cause mortality at 35 days.", 
                "measure": "Global response of antifungal therapy at day 35", 
                "safety_issue": "Yes", 
                "time_frame": "35 days"
            }, 
            {
                "description": "The primary aim of this study is to compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis. In order to accomplish the first aim, this study will utilize a controlled comparative effectiveness study design. The primary effectiveness endpoint for study aim 1 is the comparison of global response at 14 days of antifungal therapy between antifungal therapeutic classes. The secondary effectiveness endpoints for study aim 1 are comparative effectiveness of the 1) global response to antifungal therapy after 35 days and 2) all-cause mortality at 35 days.", 
                "measure": "All-cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "35 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01869829"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary aim is to validate a clinical prediction model for candidemia in pediatric intensive care unit.  A subaim of this objective is to determine the incidence of invasive candidiasis in specific high risk pediatric subpopulations.  For the second aim, concurrent with the comparative effectiveness study, a prospective case-control study will be performed to validate a previously derived clinical prediction model developed to identify critically ill children with candidemia. The endpoint for study objective 2 is the confirmation of the value of a prediction model for developing candidemia in PICU patients.", 
            "measure": "Development of candidemia while in PICU", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Children's Hospital of Philadelphia", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "December 2013"
    }
}